This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Leukemia, Lymphoma or Myelodysplastic Syndrome
and you are
between 18 and 60
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a complication of transplantation where the donor graft attacks and damages some of your tissues. After stem cell transplant, all patients receive prophylactic medications against GVHD. In this research study, we are studying the safety and effectiveness of a bortezomib based GVHD prophylaxic drug combination in participants after myeloablative allogeneic stem call transplantation from a matched unrelated donor, mismatched related or unrelated donor.

Provided treatments

  • Drug: Bortezomib
  • Drug: Tacrolimus
  • Drug: Methotrexate

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01323920. The sponsor of the trial is Dana-Farber Cancer Institute and it is looking for 35 volunteers for the current phase.
Official trial title:
Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study